Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets

American Journal of Health-System Pharmacy

Volumn 56, Issue 5, 1999, Pages 454-456

  Leaf, Emily ^a   King, Jerri O ^a  

^a Naval Hospital Bremerton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM; ECONOMICS; FEMALE; HUMAN; MALE; MEDICAL RECORD; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; FEMALE; GLIPIZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033089260     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.5.454     Document Type: Article

References (17)

1. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications. 1994; 8:201-3.
2. Birkeland KI, Mowinckel P, Furuseth K et al. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care. 1994; 17:45-9.
3. Sheu WH-H, Chen Y-DI, Jeng C-Y et al. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM. Diabetes Care. 1995; 18:1582-7.
4. Huupponen R, Seppälä P, Iisalo E. Glipizide pharmacokinetics and response in diabetics. Int J Clin Pharmacol Ther Toxicol. 1982; 20:417-22.
5. 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther. 1986; 39:318-24.
6. Rosenstock J, Corrao PJ, Goldberg RB et al. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther. 1993; 15:1031-40.
7. Jaber LA, Wenzloff NJ, Komanicky P et al. An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide. J Clin Pharmacol. 1990; 30:181-8.
8. Groop L, Groop P-H, Stenman S et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care. 1987; 10:671-8.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
10. Lasker RD. The Diabetes Control and Complications Trial: implications for policy and practice. N Engl J Med. 1993; 329:1035-6.
11. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Position statement. Diabetes. 1993; 42:1555-8.
12. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
13. Berelowitz M, Schade DS, Fischette C et al. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994; 17:1460-4.
14. Kilo C, Meenan A, Bloomgarden Z. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther. 1992; 14:801-12.
15. Stenman S, Melander A, Groop P-H et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 1993; 118:169-72.
16. Henry RR, Genuth S. Forum one: current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:175-7.
17. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150:1881-4.